Y

et another showdown over the high cost of medicines is taking place in Ireland, where the government and the maker of a cystic fibrosis treatment are locked in a battle that has enraged and worried patients.

The struggle is over Orkambi, a drug sold by Vertex Pharmaeuticals that has a price tag of about $170,000 a year. But Ireland’s National Centre for Pharmacoeconomics determined the medicine would be cost effective only if it were priced at about $32,000 per patient and did not recommend reimbursement. Consequently, Ireland’s Health Service Executive has so far refrained from providing coverage.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy